Navigation Links
Spectral's EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
Date:4/9/2008

may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
3. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
8. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
9. Phase III Trial Finds Pharmaxis Bronchitol Effective
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  Propanc Health Group Corporation (OTCBB: PPCH) is ... development of cancer treatments for patients with pancreatic ... PRP, a patented formulation consisting of two pro-enzymes, ... the enzyme amylase designed to synergistically enhance anti-cancer ... anti-cancer agents working in combination with pro-enzymes, which ...
(Date:4/23/2015)... FRANCISCO, CA (PRWEB) April 23, 2015 ... delivery, today announced that the United States Patent and ... the Company’s NANOPOR™ technology. US Pat. ... covers Delpor’s microfabricated drug delivery device for ... Delpor’s proprietary NANOPOR™ technology for the sustained (zero-order) release ...
(Date:4/22/2015)... - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today announced that it will report ... May 7, 2015 after the close of the market. ... for 4.30 pm ET (1.30 pm PT) to discuss ... conference call will be webcast over the internet and ... media and the general public. To access the webcast ...
(Date:4/22/2015)... Steep Hill, the industry leader in ... has opened an investment round of $5 million ... common stock investment round will be offered through ... to encourage funding of small businesses by easing ... largely relied on friends and family, venture capitalists ...
Breaking Biology Technology:Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... 20 Humanitarian, Dr. Gary Michelson,is "making an ... Gilbreath, Executive Director of Found Animals Foundation (Found,Animals) ... Found Animals and its strategic partner the Alliance ... launch of The Michelson Prize in,Reproductive Biology at ...
... The Board of Directors,of Eli Lilly and Company ... as a,new member, effective December 1, 2008. Oberhelman, 55, ... is a member of Caterpillar,s,executive office. As a member ... audit committee and finance committee. He will stand for,election ...
... ORANGE COUNTY, Calif., Oct. 20 Beckman,Coulter, Inc. ... Board of Directors,declared a quarterly dividend payout of ... payable on November 17, 2008 to all,stockholders of ... the 78th,consecutive, quarterly payout of dividends., (Logo: ...
Cached Biology Technology:Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4Douglas Oberhelman Elected to Lilly Board of Directors 2Douglas Oberhelman Elected to Lilly Board of Directors 3
(Date:3/24/2015)... ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of the ... report to their offering. This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Biometrics - Global Strategic Business Report" report to their ... Iris Biometrics in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Latin America . Annual ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... found that pre-existing malaria prevents secondary infection by another ... iron availability in the liver of the host. This ... Nature Medicine and has important implications for ... affects millions of individuals worldwide. The study was ...
... a class of compounds that could be a boon to ... study, published online in Nature Chemical Biology on ... and selectively block the activity of a large and diverse ... hydrolase-blocking compounds have been turned into drugs to treat obesity, ...
... May 15, 2011) An international research team ... Institute for Breast Cancer Research at Princess Margaret Hospital ... the process whereby tumour cells adapt and survive under ... published today in Genes and Development ( ...
Cached Biology News:Malaria against malaria: A pre-existing malaria infection can prevent a second infection 2Malaria against malaria: A pre-existing malaria infection can prevent a second infection 3Scientists find new class of compounds with great potential for research and drug development 2Scientists find new class of compounds with great potential for research and drug development 3Cancer scientists discover new way breast cancer cells adapt to environmental stress 2
...
Chicken anti-EEA1...
... Cell Dissociation Buffers are membrane-filtered ... salts chelating agents and cell-conditioning agents ... balanced salt solution or Ca2+- ... dissociation of mammalian cells from support ...
Request Info...
Biology Products: